Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
-
Randomized Controlled Trial
Effect of a single dose of lidocaine and ketamine on intraoperative opioids requirements in patients undergoing elective gynecological laparotomies under general anesthesia. A randomized, placebo controlled pilot study.
Background and goal of study: there is evidence that perioperative intravenous ketamine and lidocaine reduce postoperative pain, postoperative opioids consumption, shortens hospital stay and accelerates intestinal function recovery. However, it has not been studied the beneficial effects in the intraoperative period. The aim of this study was to evaluate the effect of a single dose of lidocaine and ketamine on intraoperative opioids requirements in patients undergoing elective gynecological laparotomies under general anesthesia. ⋯ our results do not support the use of intraoperative single dose of lidocaine or ketamine to reduce postoperative pain and postoperative opioids consumption after open gynecological surgery. However, they seem to decrease intraoperative opioids requirements and shorten emergence time. Nevertheless, these findings should be validating in further studies with large sample size.
-
Observational Study
Chemotherapy near the end of life; assessment of the clinical practise in onco-hematological in adult patients.
ensure a good quality of life in the last phase of onco- hematological patients should be the primary goal, despite this, we have little data at European level and published studies are contradictory. Nevertheless, most of them agree saying that administrating chemotherapy near the end of life impacts negatively in the patients quality of life. The main objective of this study is to analyze the treatment non-aggressiveness parameters in onco-hematological patients. The secondary objective is to do a describing study of the clinical variables of the patients who receive chemotherapy at the end of life and the treatments more used. ⋯ according to the Earle et al. criteria, our population had been treated aggressively. We need more scientific evidence with consolidate date that allows us to establish a unified criteria for the selection of patients with advanced cancer who may benefit from receiving antineoplasic treatments.
-
Observational Study
Smartphone applications for cancer patients; what we know about them?
one of the groups that can benefit most from healthcare applications, are cancer patients. However, not all applications have a sufficient level of evidence. Our objective is to analyze the characteristics of mobile healthcare applications for cancer patients and know the reliability of their information. ⋯ there are many benefits that are expected from these applications. However, we detected a lack of validity of the information, as well as lack of update of the data. To prevent these apps from becoming a safety problem rather than a useful tool for patients, regulation should be put in place.
-
to develop the different factors involved in the physiopathology of trauma-induced coagulopathy, through a review of publications on the matter; as well as to assess the evidence available on the treatment of critical bleeding and the recommendations by clinical practice guidelines. ⋯ the physiopathology of the trauma-induced coagulopathy is a more complex matter and involves more factors than was initially assumed. The early treatment of the coagulopathy is critical for the initial management of the critical bleeding. However, the use of blood derivatives should be rational and based on homogeneous and high-quality scientific evidence. The main cornerstones for the treatment of critical bleeding are: fluid therapy, fibrinogen concentrate, prothrombin complex concentrate, plasma, erythrocyte or platelet concentrates, tranexamic acid, and calcium. Their administration should be assessed depending on the clinical condition of each patient.